NewLink Genetics (NLNK) said Monday it will collaborate with AstraZeneca (AZN) to evaluate the combination of indoximod and durvalumab along with standard of care chemotherapy in the treatment of metastatic pancreatic cancer.
Indoximod is NewLink Genetics’ small molecule IDO pathway inhibitor and durvalumab is AstraZeneca’s anti-PD-L1 monoclonal antibody. Chemotherapy is the standard of care treatment.
A placebo-controlled phase 2 study will evaluate the efficacy and safety of the drug combination compared to Celgene’s (CELG) Abraxane alone. Patients will also be enrolled into a smaller cohort evaluating the combination of durvalumab with Abraxane.
The phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as the study sponsor. NewLink said it does not expect its share of the trial expense to have a material effect on its financial position.